BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 15535857)

  • 1. New targets for therapy in breast cancer: farnesyltransferase inhibitors.
    Head J; Johnston SR
    Breast Cancer Res; 2004; 6(6):262-8. PubMed ID: 15535857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein farnesyltransferase inhibitors.
    Head JE; Johnston SR
    Expert Opin Emerg Drugs; 2003 May; 8(1):163-78. PubMed ID: 14610919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyltransferase inhibitors: potential role in the treatment of cancer.
    Cox AD
    Drugs; 2001; 61(6):723-32. PubMed ID: 11398905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitors in breast cancer therapy.
    Dy GK; Adjei AA
    Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
    Moasser MM; Rosen N
    Breast Cancer Res Treat; 2002 May; 73(2):135-44. PubMed ID: 12088116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving therapies: farnesyltransferase inhibitors.
    Purcell WT; Donehower RC
    Curr Oncol Rep; 2002 Jan; 4(1):29-36. PubMed ID: 11734111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical evaluation of farnesyltransferase inhibitors.
    Baum C; Kirschmeier P
    Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer?
    O'Regan RM; Khuri FR
    Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors: mechanism and applications.
    Prendergast GC; Rane N
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2105-16. PubMed ID: 11772308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting Ras signaling in the therapy of breast cancer.
    Li T; Sparano JA
    Clin Breast Cancer; 2003 Feb; 3(6):405-16; discussion 417-20. PubMed ID: 12636885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of farsenyl transferase inhibitors as anticancer agents].
    Cestac P; Doisneau-Sixou S; Favre G
    Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyltransferase inhibitors in myelodysplastic syndrome.
    Feldman EJ
    Curr Hematol Rep; 2005 May; 4(3):186-90. PubMed ID: 15865870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
    Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
    Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.
    de Bono JS; Tolcher AW; Rowinsky EK
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):79-92. PubMed ID: 14613029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.